fbpx Skip to main content

MONDAY, Jan. 4, 2021 (HealthDay News) — For nursing home residents with COVID-19, the odds of 30-day mortality are increased with older age, male sex, and impaired cognitive and physical function, according to a study published online Jan. 4 in JAMA Internal Medicine.

Orestis A. Panagiotou, M.D., Ph.D., from the Brown University School of Public Health in Providence, Rhode Island, and colleagues identified risk factors for 30-day all-cause mortality among 5,256 nursing home residents with COVID-19-related symptoms and confirmed severe acute respiratory syndrome coronavirus 2 infection at 351 U.S. nursing homes.

The researchers found that the odds of death were 1.46, 1.59, and 2.14 times higher for residents aged 80 to 84, 85 to 89, and 90 years or older compared with those aged 75 to 79 years. Compared with men, women had a lower risk for 30-day mortality (odds ratio, 0.69). Diabetes and chronic kidney disease were associated with mortality (odds ratios, 1.21 and 1.33, respectively). An increased risk for 30-day mortality was also seen in association with fever, shortness of breath, tachycardia, and hypoxia (odds ratios, 1.66, 2.52, 1.31, and 2.05, respectively). The odds of death were increased for residents with moderate cognitive impairment and severe cognitive impairment compared with cognitively intact residents (odds ratios, 2.09 and 2.79, respectively) and for those with moderate and severe versus no or limited impairment in physical function (odds ratios, 1.49 and 1.64, respectively).

“These findings can be used to aid in prognostication and risk stratification in this population to inform treatment decisions and conversations around goals of care,” the authors write.

Several authors disclosed financial ties to health care industries.

You May Also Like::  Disease Under Control for Only 38.1 Percent With Treated Hypertension in the U.K.

Abstract/Full Text


“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More